We previously showed that in chronic myeloid leukaemia (CML), it is possible to induce costimulatory molecules, CD80/CD86, on leukaemia cells by culturing adherent peripheral blood mononuclear cells from these patients with IL-4 and GM-CSF. In addition to the expression of CD80/CD86 molecules, some of the leukaemia cells also expressed the dendritic cell marker, CD1a. When these leukaemia cells were used in mixed lymphocyte leukaemia reactions, they mediated autologous T cell proliferation not seen when fresh leukaemia cells were used as the stimulator cells. In this study, we showed that reinfusion of these immunogenic leukaemia cells to the autologous hosts resulted in priming in vivo of T cells so that they could respond to subsequent rechallenge in vitro with fresh autologous leukaemia cells. Although cytotoxic T cells against leukaemia cells were not demonstrated, these T cells could proliferate and produce interferon-␥ when cocultured in vitro with the leukaemia cells. Our findings therefore provide further evidence for the immunogenicity of these cultured leukaemia cells in CML. Keywords: CML; immunogenicity; costimulatory molecules
activation pathway is becoming increasingly recognised in the pathophysiology of tumour immunity.
In CML, T cell immunity may play a fundamental role in the control of leukaemia cell growth following allogeneic bone marrow transplantation. 1 In the autologous setting, we previously provided evidence supporting the immunogenicity of the leukaemia cells in CML. We observed abnormal T cell receptor V␤ gene usage by peripheral blood T-lymphocytes in patients with CML. 2 In addition, leukaemia reactive T cells in the autologous host could be isolated either de novo 3 or following autologous peripheral blood stem cell transplantation. 4 Although these effector cells are present, anti-leukaemic responses were ineffective in vivo because the T cells were normally anergic to the autologous leukaemia cells. T cell reactivity to leukaemia cells could, however, be re-established following pre-incubation of the T cells in high-dose recombinant interleukin-2.
There are many possible reasons why T cell anergy to autologous leukaemia cells occurs. However, the most likely cause is lack of the appropriate immune costimulatory molecules on the leukaemia cells which could provide the second signal needed for optimal T cell activation. De novo tumour cells do not express T cell costimulatory molecules. Transfectant of costimulatory molecule cDNA 5, 6 or fusion of a tumour cell with antigen presenting cell 7 to express CD80/CD86 resulted in T cell responses to these tumours, supporting the importance of these costimulatory molecules in eliciting effective T cell responses. We recently demonstrated that it was possible to induce these costimulatory molecules on leukaemia cells by culturing adherent leukaemia cells in IL-4 and GM-CSF. 8 When these leukaemia cells were used in mixed lymphocyte leukaemia reactions, they mediated autologous T cell proliferation not seen when fresh leukaemia cells were used as the stimulator cells. Other workers have demonstrated the ability to generate leukaemic dendritic cells from patients with CML. 9, 10 By virtue of their surface properties, these immunogenic leukaemia cells may be able to present leukaemia antigens more efficiently than fresh leukaemia cells and provide the second signal needed for the generation of effective T cell responses. Therefore, it may be feasible to utilise these immunogenic leukaemia cells in vaccination of CML without the need to pulse these cells with any putative antigens such as the bcr-abl junctional peptides.
Here, we determine the feasibility of using these immunogenic leukaemia cells for vaccination. We demonstrate that reinfusion of leukaemia cells previously cultured in IL-4 and GM-CSF primed the T cells in vivo so that they could respond with proliferation and cytokine release to subsequent challenges with fresh autologous leukaemia cells.
Materials and methods

Isolation of peripheral blood mononuclear cells (PBMCs)
Peripheral blood was collected into heparin and the PBMCs isolated using Histopaque 1077 (Sigma, Poole, UK) density gradient centrifugation. Light density cells were harvested, washed three times in phosphate-buffer saline (PBS) and resuspended in RPMI 1640 medium (Gibco, Paisley, UK) supplemented with 10% fetal calf serum (FCS) (Gibco) before being used for subsequent experiments.
In vitro induction of costimulatory molecules from adherent leukaemia cells
Leucapheresis was carried out to enable the harvesting of a large number of leukaemic PBMC. Fresh PBMCs were prepared by Ficoll-Hypaque centrifugation, washed and resuspended in RPMI 1640 + 10% FCS. PBMCs were incubated at 37°C in 5% CO 2 for 2 h. Non-adherent cells were removed by three gentle washes. The adherent leukaemia cells were then cultured in RPMI 1640 + 10% FCS, supplemented with GM-CSF (800 U/ml) (Sandoz, Camberley, UK) and IL-4 (500 U/ml) (Schering-Plough, UK, Welwyn Garden City, UK) for 7 days. The cells were pulsed with a control antigen, Keyhole Limpet Haemocyanin (25 g/ml) (Calbiochem, Nottingham, UK) on days 1 and 6 of culture.
Immunophenotyping
This was carried out on all the cultured cells using a fluorescence-activated cell scan (FACScan) (Becton Dickinson, San Jose, CA, USA) and analysed by Lysis II programme. Monoclonal antibodies used were: PE-conjugated mouse antihuman CD1a (Serotec, Oxford, UK) and CD80 (B7-1, Becton Dickinson UK) and FITC-conjugated mouse antihuman CD86 (B7-2, Serotec, UK), CD11c, CD14, CD3 and HLA-DR antibodies (Becton Dickinson). One stage direct staining was carried out. Briefly, the cells were first washed twice in wash buffer (PBS + 2% bovine serum albumin and 0.5% sodium azide). Antibodies at manufacturer's recommended concentrations were added to each cell pellet and the cells were incubated on ice for 30-40 min before being washed three times and resuspended in 2% paraformaldehyde solution ready for analysis.
T cell proliferation assays
Fresh PBMCs were seeded in 96-well flat-bottom microtitre plates (Becton Dickinson, San Jose, CA, USA) at 1 × 10 5 per well in 200 l of RPMI 1640 supplemented with 10% FCS, 1 mm-glutamine, 100 U/ml penicillin, 100 g/ml streptomycin and 25 mm Hepes (referred to as complete medium). KLH or irradiated fresh leukaemia cells were added to the cultures in various final concentrations and the cultures were incubated at 37°C in 5% CO 2 . Cells were pulsed on day 4 with 0.5 Ci methyl-3 H-thymidine per well and harvested 18 h later. Methyl-3 H-thymidine incorporation was measured by liquid scintillation counting. Results from triplicate cultures are given as the arithmetic means ± s.d. Supernatants were harvested after 72 h and assayed for the production of IFN-␥ using a commercially available ELISA kit (Genzyme, Cambridge, MA, USA).
Cytotoxic T-lymphocyte (CTL) assays
PBMCs obtained before and weekly after each leukaemia cell reinfusion were incubated in 96-well round bottom-microtitre plates at 1 × 10 5 per well in a volume of 150 l of RPMI 1640 + 10% FCS, irradiated fresh autologous leukaemia cells and IL-2 (50 U/ml) (Chiron, Harefield, UK) for 1 week. The cells were then assayed for their cytotoxic ability for various targets in a standard 4-h Cr-release, calculated as follows:
% release = (sample counts − spontaneous counts) (maximum counts − spontaneous counts × 100.
ELISA measurements of antibodies
Antibody responses to vaccination were measured by ELISA as described previously. 11 Briefly, the microtitre plates were coated with KLH (50 g/ml) overnight. Pre-and post-vaccination serum samples were serially diluted and allowed to bind to the target proteins. The binding of anti-KLH IgM antibodies was detected by mouse anti-human IgM antibodies (Sigma) followed by horse-radish peroxidase-conjugated goat anti-mouse IgG antibodies (Sigma). The binding anti-KLH IgG antibodies was detected using biotinylated goat antihuman IgG antibodies (Sigma), followed by peroxidaseconjugated streptavidin (Sigma).
Results
Leukaemia cell reinfusion
Two patients with chronic phase CML were studied after informed consent. CML had been diagnosed in both patients 3 years previously. Patient 1 was receiving IFN-␣ and patient 2 hydroxyurea at the time of study. Induction of costimulatory molecules was successfully carried out from adherent leukaemia cells using a combination of IL-4 and GM-CSF, as presented in our previous study, by fluorescence in situ hybridisation for the bcr-abl fusion genes in CD1a-sorted cells from these two patients. 8 The cells showed typical dendritic cell morphology, exhibiting finger-like projections of lamellopodia. A total of 13.2 × 10 6 cells were generated from patient 1 and 60 × 10 6 cells from patient 2. The cells expressed CD80, CD86 and CD11c (Figure 1 ). In addition, some of the cells also expressed CD1a molecules and were negative for CD14. These cells functioned efficiently in autologous mixed lymphocyte leukaemia reactions (Figure 2) . The cultured leukaemia cells were then decanted from the flasks and adherent cells dislodged by vigorous shaking with PBS. Pooled cells were washed three times in PBS and divided into three equal aliquots, each to be administered on each occasion. One aliquot was reinfused fresh and consisted of fresh cultured leukaemia cells resuspended in PBS/4% human albumin solution. The other two aliquots, resuspended in cooled PBS containing 4% human albumin solution and 7.5% dimethyl sulphoxide, were frozen using the Planer ratecontrolled freezer effectively at 1°C per min. Frozen cells were stored in the vapour phase of liquid nitrogen. When required for reinfusion, cells were rapidly thawed to 37°C and diluted five-fold with PBS and immediately injected intravenously over 15 min. Cell recovery and trypan blue viability were Ͼ90%.
On each occasion, 10 mg of an anti-histamine, chlorpheniramine, was administered intravenously prior to leukaemia cell reinfusion. Cell reinfusions were administered intravenously over 15 min on a weekly basis, starting at week 0. On all three occasions, both patients tolerated the vaccination without any adverse reactions.
Immune responses to a control vaccine
We first determined the immune responses to control vaccine. T cell proliferative and B cell antibody responses to KLH were measured. Prior to leukaemia cell reinfusions, a primary T cell proliferative response was not observed with a KLH concentration of up to 50 g/ml. However, T cells isolated from the patients' peripheral blood on successive weeks following cell reinfusions showed that in vivo priming of the T cells to KLH occurred after reinfusion with KLH-pulsed cultured leukaemia cells so that T cells could now proliferate in response to in vitro KLH restimulation. The proliferative responses were observed after the second reinfusion and increased with successive vaccinations (Figure 3a and b) . Using an ELISA detection system, the presence of anti-KLH antibodies following KLH-pulsed leukaemia cell reinfusion was detected repeatedly (Figure 4a and b) . We found a predominantly anti-KLH IgG response. The anti-KLH IgG antibody response was detected, even at a serum dilution of 1:400.
These results therefore indicate successful immune responses to the control vaccine and suggest that the immune systems of patients were able to mount immune responses against an antigen presented by the vaccination strategy we have used.
T cell responses to leukaemia cell reinfusion
To determine the relevance of the mixed lymphocyte leukaemia reactions observed using cultured leukaemia cells in the context of fresh leukaemia cells, T cells primed in vivo with the CD80/CD86
+ leukaemia cells were cocultured with fresh leukaemia cells. Following reinfusion, at a stimulator:responder cell ratio as low as 1:10, the T cells were able to proliferate in response to autologous leukaemia cells in the coculture system (Figure 5a and b) . In addition to T cell proliferation, there was an associated production of IFN-␥ by the peripheral T cells isolated from both patients following leukaemia cell reinfusion upon in vitro coculture with fresh autologous leukaemia cells (Figure 6a and b) . These results therefore suggest that in vivo primed T cells recognise epitopes on the fresh leukaemia cells which had been presented by the CD80/CD86 + leukaemia cells. Using our CTL detection protocol, we were, however, unable to detect any specific CTL activity in the peripheral blood of the both patients at an input:target ratio of 20:1. This is in keeping with our in vitro study 8 which showed no cytotoxic activity against fresh leukaemia cells by immunogenic leukaemia cell-primed T cells.
Changes in haematological parameters following vaccination
There were no apparent changes in the haematological parameters following reinfusion of the cultured leukaemia cells in either patient.
Discussion
T cells are potent cellular effectors of the immune system. They possess memory and can respond to rechallenge by the same antigen. If a tumour-specific immune response can be elicited, immunotherapy would appear an ideal therapeutic approach. Active tumour could be induced into remission using chemotherapy and disease progression prevented by long-term tumour immunosurveillance provided by memory T cells. However, the ability to generate a strong and uniform antitumour immune response depends on several factors. While the nature of the antigen may be an important consideration, the optimal and effective processing and presentation of antigens to the immune system is also paramount. In addition, the contribution of activation signals from costimulatory molecules is vital. In keeping with our previous study, 8 we were able to induce the expression of CD80 and CD86 molecules on the surface of leukaemia cells using a combination of IL-4 and GM-CSF. The increased expression of these immune costimulatory molecules was associated with improvement in the immunogenicity of leukaemia cells to autologous T cells, as determined by mixed lymphocyte leukaemia reactions.
Demonstration of the ability to induce autologous T cell responses using these cultured leukaemia cells suggests an opportunity for manipulation of the CML host immune system to produce an anti-leukaemic response. An appropriate approach to this is to determine if in vitro immune responses can be reproduced in vivo. In this study, we therefore set out to investigate the feasibility of such a vaccination strategy and determine the immune responses in vivo to these immunogenic leukaemia cells in two CML patients following reinfusion of cultured leukaemia cells. Due to previous chemotherapy and presence of an active malignant disease, which potentially could result in immune suppression in the patients, it was necessary to include a control vaccine in our vaccination protocol. The ability of the immune system to respond to vaccination in these patients and the appropriateness of the vaccination strategy were first confirmed by the generation of T cell proliferative responses to KLH and production of anti-KLH antibodies following vaccination.
We found that IL-4/GM-CSF cultured leukaemia cells primed T cells in vivo so that T cells proliferated and produced IFN-␥ upon coculture with fresh autologous leukaemia cells, suggesting that in vivo primed T cells recognised epitopes on the fresh leukaemia cells which had been presented by the immunogenic leukaemia cells. Although CTLs for autologous leukaemia cells were not detected using T cells isolated from the patients following vaccination, the definite Th1 cytokine production may exert some anti-leukaemic effects, especially since IFN-␥ therapy has been shown to be effective in certain cases of CML. Although T cell responses were observed following vaccination, these were weak. There are many possible explanation for this. However, the most likely cause is the presence of some immune inhibitory cytokine produced by the leukaemia cells, such as IL-10. It may be interesting in future to determine the presence of any immune inhibitory cytokines in the serum. This may also provide an explanation for the failure of leukaemia cells to express these immune costimulatory molecules in vivo.
In conclusion, immune responses to cultured leukaemia cells as predicted by in vitro immunisation could be reproduced in vivo. However, further work is needed to optimise the vaccination protocol and define the group of patients best treated by this approach thus enabling evaluation of the clinical significance of these immune responses.
